-
Mashup Score: 4CRISPR genome engineering - 3 day(s) ago
Join the conversation
Source: bsky.appCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 7Affordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative | The CRISPR Journal - 1 month(s) ago
Casgevy, the world’s first approved CRISPR-based cell therapy, has been priced at $2.2 million per patient. Although this hefty price tag was widely anticipated, the extremely high cost of this and other cell and gene therapies poses a major ethical issue in terms of equitable access and global health. In this Perspective, we argue that lowering the prices of future CRISPR therapies is an urgent ethical imperative. Although we focus on Casgevy as a case study, much of our analysis can be extrapolated to the controversies over affordable access to other gene and cell therapies. First, we explain why this first-of-its-kind CRISPR therapy might be so expensive. We then analyze the ethical issues of equity and global health of early CRISPR treatments. Next, we discuss potential solutions to lower the prices of CRISPR gene therapies. We conclude that the approval of CRISPR transforms our obligations of justice and compels us to bring future gene therapies to the maximum possible number of p
Source: www.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 14Genome Editing Therapy for the Blood: Ex Vivo Success and In Vivo Prospects | The CRISPR Journal - 1 month(s) ago
Hematopoietic stem cells (HSCs) provide the body with a continuous supply of healthy, functional blood cells. In patients with hematopoietic malignancies, immunodeficiencies, lysosomal storage disorders, and hemoglobinopathies, therapeutic genome editing offers hope for corrective intervention, with even modest editing efficiencies likely to provide clinical benefit. Engineered white blood cells, such as T cells, can be applied therapeutically to address monogenic disorders of the immune system, HIV infection, or cancer. The versatility of CRISPR-based tools allows countless new medical interventions for diseases of the blood, and rapid ex vivo success has been demonstrated in hemoglobinopathies via transplantation of the patient’s HSCs following genome editing in a laboratory setting. Here we review recent advances in therapeutic genome editing of HSCs and T cells, focusing on the progress in ex vivo contexts, the promise of improved access via in vivo delivery, as well as the ongoing
Source: www.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 57The CRISPR Journal | Vol 7, No 5 - 1 month(s) ago
The CRISPR Journal
Source: www.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 1Modular Ontologies for Genetically Modified People and their Bioethical Implications - 3 month(s) ago
Participants in the long-running bioethical debate over human germline genetic modification (HGGM) tend to imagine future people abstractly and on the basis of conventionalized characteristics familiar from science fiction, such as intelligence, disease …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 20
The CRISPR Journal
Source: www.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 1Expanding the Genome-Editing Toolbox with Abyssicoccus albus Cas9 Using a Unique Protospacer Adjacent Motif Sequence | The CRISPR Journal - 3 month(s) ago
The genome-editing efficiency of the CRISPR-Cas9 system hinges on the recognition of the protospacer adjacent motif (PAM) sequence, which is essential for Cas9 binding to DNA. The commonly used Streptococcus pyogenes (SpyCas9) targets the 5′-NGG-3′ PAM sequence, which does not cover all the potential genomic-editing sites. To expand the toolbox for genome editing, SpyCas9 has been engineered to recognize flexible PAM sequences and Cas9 orthologs have been used to recognize novel PAM sequences. In this study, Abyssicoccus albus Cas9 (AalCas9, 1059 aa), which is smaller than SpyCas9, was found to recognize a unique 5′-NNACR-3′ PAM sequence. Modification of the guide RNA sequence improved the efficiency of AalCas9-mediated genome editing in both plant and human cells. Predicted structure-assisted introduction of a point mutation in the putative PAM recognition site shifted the sequence preference of AalCas9. These results provide insights into Cas9 diversity and novel tools for genome edi
Source: www.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 0Prime Editing of Vascular Endothelial Growth Factor Receptor 2 Attenuates Angiogenesis In Vitro | The CRISPR Journal - 3 month(s) ago
Vascular endothelial growth factor receptor (VEGFR)-2 is a key switch for angiogenesis, which is observed in various human diseases. In this study, a novel system for advanced prime editing (PE), termed PE6h, is developed, consisting of dual lentiviral vectors: (1) a clustered regularly interspaced palindromic repeat-associated protein 9 (H840A) nickase fused with reverse transcriptase and an enhanced PE guide RNA and (2) a dominant negative (DN) MutL homolog 1 gene with nicking guide RNA. PE6h was used to edit VEGFR2 (c.18315T>A, 50.8%) to generate a premature stop codon (TAG from AAG), resulting in the production of DN-VEGFR2 (787 aa) in human retinal microvascular endothelial cells (HRECs). DN-VEGFR2 impeded VEGF-induced phosphorylation of VEGFR2, Akt, and extracellular signal-regulated kinase-1/2 and tube formation in PE6h-edited HRECs in vitro. Overall, our results highlight the potential of PE6h to inhibit angiogenesis in vivo.
Source: www.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 0Challenging the Boundaries Between Treatment, Prevention, and Enhancement in Human Genome Editing | The CRISPR Journal - 3 month(s) ago
Traditional distinctions between treatment and enhancement goals for human genome editing (HGE) have animated oversight considerations, yet these categories have been complicated by the addition of prevention as a possible target for HGE applications. To assess the role these three categories might play in continued HGE governance efforts, we report on interviews with genome editing scientists and governance group members. While some accepted traditional distinctions between treatment and enhancement and rejected the latter as unacceptable, others argued that the concept of enhancement is largely irrelevant or not as morally problematic as suggested. Others described how preventive goals for HGE create gray zones where prevention and enhancement may be difficult to distinguish, which may stymie uses of HGE. We conclude by discussing the governance implications of these various understandings of treatment, prevention, and enhancement as HGE research moves beyond the treatment of serious
Source: www.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 4Surveying the State of CRISPR and Gene Editing | The CRISPR Journal - 5 month(s) ago
The CRISPR Journal
Source: www.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
There is a rapidly growing list of #CRISPR experts, evangelists and afficionados over at the other place... https://t.co/334vS39A0W